Get started
Author

Laura J. Eccles

Observed names: L Eccles, L. Eccles, L.J. Eccles, Laura Eccles
ORCID: 0009-0002-9543-1745
Observed ORCID: 0009-0002-9543-1745
OpenAlex ID: A5002461369
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
2022 · Julie R. Brahmer, Jong-Seok Lee, et al. · Journal of Clinical Oncology · 406
PDF
Delayed repair of radiation induced clustered DNA damage: Friend or foe?
2010 · Laura J. Eccles, Peter O’Neill, et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 234
PDF
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
2022 · Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, et al. · Journal of Thoracic Oncology · 104
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
2024 · Martin Reck, Tudor-Eliade Ciuleanu, et al. · European Journal of Cancer · 88
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
2023 · Martin Reck, Tudor-Eliade Ciuleanu, et al. · Journal of Thoracic Oncology · 78
PDF
Hierarchy of lesion processing governs the repair, double-strand break formation and mutability of three-lesion clustered DNA damage
2009 · Laura J. Eccles, Martine E. Lomax, et al. · Nucleic Acids Research · 77
PDF
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis
2023 · Kenneth O'Byrne, Evan Popoff, et al. · Lung Cancer · 31
PDF
Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks
2018 · Laura J. Eccles, Andrew C. Bell, et al. · DNA repair · 26
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
2025 · Pasi A. Jänne, Willemijn S.M.E. Theelen, et al. · Journal of Clinical Oncology · 25
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey
2023 · Hollie Bailey, Adam Lee, et al. · BMC Cancer · 25
PDF
Efficient cleavage of single and clustered AP site lesions within mono-nucleosome templates by CHO-K1 nuclear extract contrasts with retardation of incision by purified APE1
2015 · Laura J. Eccles, Hervé Menoni, et al. · DNA repair · 24
PDF
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
2022 · Julie R. Brahmer, Jong-Seok Lee, et al. · Journal of Clinical Oncology · 16
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
2022 · Sarah Goring, Nebibe Varol, et al. · Lung Cancer · 14
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
2021 · M. Reck, T.E. Ciuleanu, et al. · Annals of Oncology · 11
5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥50% from the phase II portion of KRYSTAL-7
2025 · M.C. Garassino, W.S.M.E. Theelen, et al. · Journal of Thoracic Oncology · 10
Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies
2022 · Adam Lee, Yong Yuan, et al. · Cancer Treatment and Research Communications · 10
PDF
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
2024 · Martin Reck, Tudor-Eliade Ciuleanu, et al. · Journal of Clinical Oncology · 9
PDF
LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
2022 · G. Zalcman, Y. Oulkhouir, et al. · Annals of Oncology · 7
PDF
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
2025 · Solange Peters, Meredith M. Regan, et al. · Journal of Thoracic Oncology · 5
PDF
1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
2022 · T. John, T-E. Ciuleanu, et al. · Annals of Oncology · 3
95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1
2025 · J. Zhang, A.I. Spira, et al. · Journal of Thoracic Oncology · 2
PDF
107P The evolving diagnostic and treatment landscape in metastatic non-small cell lung cancer (mNSCLC) across Europe: A real world evidence survey
2021 · H. Bailey, A. Lee, et al. · Annals of Oncology · 2
PDF
63P Treatment-free survival (TFS) in patients (pts) with mNSCLC treated with 1L nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in CheckMate (CM) 9LA
2024 · M. Reck, M. Regan, et al. · ESMO Open · 1
EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis
2023 · K. O'Byrne, E. Popoff, et al. · Journal of Thoracic Oncology · 1
PDF
Data from Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2026 · Hossein Borghaei, David Balli, et al.
Works count: 39
Citation count: 1,208
H-index: 13
I10-index: 16
Year
Topic
Type